Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
WGS · Nasdaq · United States · Services-Health Services
In shortGeneDx Holdings Corp. is loss-making, generates cash and holds more cash than debt, with revenue growing (+40.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -3.1% | 6/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -4.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -7.6% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -3.6% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.46× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.17× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -5.22 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.3% | 33/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 25.3% | 17/100 |
| Operating margin volatility | 125.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 22.1% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 212 | 235 | 203 | 305 | 428 |
| Cost of revenue | 229 | 261 | 113 | 111 | 129 |
| Gross profit | (17) | (27) | 90 | 194 | 298 |
| Research & development | 105 | 86 | 58 | 46 | 72 |
| Operating income | (446) | (668) | (181) | (23) | (13) |
| Interest expense | 2.8 | 3.2 | – | – | – |
| Pre-tax income | (245) | (598) | (177) | (53) | (21) |
| Income tax | 0 | (49) | (0.9) | (0.3) | (0.1) |
| Net income | (245) | (549) | (176) | (52) | (21) |
| Diluted EPS | −$2.27 | −$53.63 | −$7.23 | −$1.94 | −$0.73 |
| Diluted shares (millions) | 108 | 10 | 24 | 27 | 29 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
−5.22 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 3, 2026